Pulmonx to Detail Growth Strategy at Key Investor Conference

REDWOOD CITY, CA – April 28, 2026 – Pulmonx Corporation, a medical technology firm specializing in treatments for severe lung disease, announced today it will present at the upcoming Bank of America Securities 2026 Health Care Conference. The presentation, scheduled for May 12 in Las Vegas, provides a high-stakes platform for the company to address the financial community as it navigates a landscape of improving financials, persistent stock volatility, and intensifying competition in the respiratory care market.

While such conference appearances are standard investor relations activities, this particular event comes at a pivotal moment for the Nasdaq-listed company (LUNG). Investors and analysts will be closely watching for insights into the company's strategy for sustaining growth, expanding market adoption of its flagship Zephyr® Valve, and defending its position against emerging rivals. The presentation follows a series of significant financial developments, including a stronger-than-expected earnings report for 2025 and a newly secured credit facility, setting the stage for a detailed discussion on its path forward.

A Financial Check-Up Ahead of the Big Stage

Pulmonx enters the conference season on a positive financial note, having demonstrated notable progress in its fiscal discipline. The company reported its full-year 2025 results in early March, revealing worldwide revenue of $90.50 million, an 8% increase over the prior year. More significantly, it managed to narrow its annual losses by over 4% to -$54.00 million. The fourth quarter of 2025 was particularly strong, with gross margins climbing to 78% and operating expenses falling by 11%. This performance culminated in a net loss per share of $0.25, handily beating analyst consensus estimates.

Bolstering its financial position, Pulmonx also announced the closing of a new five-year credit facility of up to $60 million in March. This move provides the company with increased financial flexibility to fund its operations and growth initiatives. However, despite these positive indicators, the company's stock has experienced significant volatility and has underperformed both the broader U.S. market and the medical equipment industry over the past year. This disconnect between operational improvements and market valuation makes the upcoming presentation particularly crucial.

Analysts remain cautiously optimistic, with consensus ratings leaning towards a “Moderate Buy.” Price targets from various analysts suggest a significant potential upside, with some forecasts projecting a stock value more than double its current trading price. “Pulmonx is the established leader in a niche but critical market,” noted one healthcare analyst. “The challenge has been translating that clinical leadership into sustained, profitable growth that satisfies Wall Street. We’ll be listening for a clear roadmap on how they plan to accelerate commercial adoption and drive toward profitability.” The presentation also comes just two weeks after the company is expected to release its first-quarter 2026 earnings, ensuring that its latest performance figures will be fresh in the minds of the audience.

Beyond the Balance Sheet: A Breakthrough for Patients

At the core of Pulmonx's story is its innovative technology aimed at a patient population with few viable options. The company's lead product, the Zephyr Endobronchial Valve, is a minimally invasive treatment for severe emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD). For patients who remain profoundly symptomatic despite medication, the condition severely impacts their ability to breathe and perform daily activities, leading to a quality of life that has been compared unfavorably to that of stage 4 lung cancer patients.

The Zephyr Valve procedure involves placing tiny, one-way valves in the airways to block off the most diseased parts of the lungs. This allows healthier lung tissue to expand and function more efficiently, reducing hyperinflation and helping patients breathe more easily. The U.S. Food and Drug Administration (FDA) designated the Zephyr Valve a “breakthrough device,” expediting its review and approval process. Today, it is considered a standard of care in global treatment guidelines and is commercially available in more than 25 countries.

To bolster its clinical leadership, Pulmonx continues to invest heavily in evidence generation. The company is actively enrolling patients in several studies, including the ZEVR registry in the United States to gather long-term real-world data. Furthermore, the COMPLETE-1 study is exploring an innovative combination therapy, pairing the Zephyr Valve system with a surgical technique to treat a broader group of emphysema patients who have what is known as 'collateral ventilation,' a condition that has historically limited the effectiveness of valve-only treatments. Success in this area could significantly expand the addressable patient market and provide a powerful new talking point for the company.

Navigating a Competitive Respiratory Market

While Pulmonx is widely considered the category leader in bronchoscopic lung volume reduction (BLVR), it does not operate in a vacuum. The global emphysema treatment market was valued at nearly $5 billion in 2025 and is projected to grow to over $8.5 billion by 2035, attracting a host of competitors with novel technologies.

Among them is Apreo Health, which is developing a device for severe emphysema that may be suitable for a wider patient population and has shown a potentially lower rate of complications in early studies. Apreo recently raised $130 million to fund a pivotal trial and early commercialization efforts, signaling a serious competitive threat on the horizon. Another company, Uptake Medical Technology, is pioneering a surgical-free vapor ablation therapy. Beyond device-based competitors, large pharmaceutical companies like AstraZeneca offer advanced inhaler therapies, such as BREZTRI AEROSPHERE, that provide maintenance treatment for a broad swath of COPD patients.

This competitive pressure underscores the importance of Pulmonx's strategic messaging. At the Bank of America conference, executives will likely be tasked with articulating how their proprietary assessment systems, like the Chartis Pulmonary Assessment System, create a diagnostic and therapeutic ecosystem that provides a durable competitive advantage. Investors will want to understand the company's strategy for accelerating physician training, expanding reimbursement coverage, and driving deeper penetration into a market that remains largely underserved. Based on past investor presentations, the company is expected to emphasize its robust body of clinical evidence from multiple randomized controlled trials, its experienced management team, and the vast $12 billion market opportunity it aims to capture.